Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy

Table 2 Treatment regimens and hepatic tumor response, n (%)

Variable	Patients (n = 28)
Anti-PD-antibody treatment cycle, median (IQR)	1 (1-1)
Number of TACE treatments, median (IQR)	4 (3-5.75)
Anti-PD-1 antibody class
Tislelizumab	6 (21.4)
Sintilimab	12 (42.9)
Camrelizumab	7 (25.0)
Pembrolizumab	3 (10.7)
TKI class
Lenvatinib	19 (67.9)
Donafenib	5 (17.9)
Apatinib	3 (10.7)
Sorafenib	1 (3.6)
Optimal tumor response according to mRECIST
PR	14 (50.0)
CR	14 (50.0)

PD-1: Programmed cell death protein 1; TACE: Transarterial chemoembolization; IQR: Interquartile range; ICI: Immune checkpoint inhibitor; TKI: Tyrosine kinase inhibitor; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; PR: Partial response; CR: Complete response.